Articles Vol. 64 No. 1 27/12/2022

4. THE EFFICACY OF SECOND-LINE TREATMENT WITH DOCETAXEL FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER STAGE IIIB-IV AT E HOSPITAL

Ngo Thi Phuong1,2, Doan Huu Nghi1,2
1 E Hospital
2 Bệnh viện E
Corresponding author: phuongvivid@gmail.com
DOI: 10.52163/yhc.v64i1.567
17 Views
1 Downloads
Keywords
Non-small cell lung cancer, second-line chemotherapy, Docetaxel.
Abstract

Objectives: To evaluate the efficacy of second-line treatment with Docetaxel for patients with nonsmall cell lung cancer (NSCLC) stage IIIB – IV at E Hospital.
Study subjects and methods: A retrospective, cross-sectional study including all patients with
NSCLC state IIIB-IV and performance status of 0-1, who had had disease progression after first-line
treatment and received second-line treatment with Docetaxel in a single-regimen at 75 mg/m2 of
body surface area every three weeks from 1/2016 to 12/2021 at E Hospital. Patients’ response was
evaluated using the “Response Evaluation Criteria in Solid Tumours,” “Disease Control Rate,” and
Progression-free survival. In addition, the rate of patients who survived without disease progression
was evaluated using the Kaplan-Meier curve and the association of different factors with that rate
was estimated using Cox’s proportional hazard regression.
Results: 57 patients were included in this study (mean age 62.3±7.5 years, 46 were male). Our research
included 41 (71.9%) patients with a smoking history. Patients with stage IV disease accounted for
96.4% of the study cohort. The most common histopathology was carcinoma, accounting for 80.7%.
We found that after three cycles, 17.5% (n=10) had a response, no patient had a complete response,
and the disease control rate was 66.7%. The median progression-free survival time was x months
(interquartile range: x – y months).
Conclusion: Patients with NSCLC stage IIIB – IV who had failed first-line therapy had a reasonably
good progression-free survival after receiving second-line treatment with Docetaxel at 75mg/m2 of
the body surface.

References
[1]
Siegel RL, Miller KD, Jemal A Cancer Statistics, Google Scholar
[2]
CA: a cancer journal for clinicians. Jan Google Scholar
[3]
;67(1):7-30. doi:10.3322/caac.21387 Google Scholar
[4]
Nasim F, Sabath BF, Eapen GA, Lung Cancer. Google Scholar
[5]
The Medical clinics of North America. Google Scholar
[6]
May 2019;103(3):463-473. doi:10.1016/j. Google Scholar
[7]
mcna.2018.12.006 Google Scholar
[8]
Rafei H, El-Bahesh E, Finianos A, Nassereddine Google Scholar
[9]
S, Tabbara I. Immune-based Therapies for Nonsmall Cell Lung Cancer. Anticancer research. Google Scholar
[10]
Feb 2017;37(2):377-387. doi:10.21873/ Google Scholar
[11]
anticanres.11330 Google Scholar
[12]
Travis WDBE, Burke AP, Marx A, AG. N. WHO Google Scholar
[13]
Classification of Tumours of the Lung, Pleura, Google Scholar
[14]
Thymus and Heart. 4th ed. IARC Press; 2015. Google Scholar
[15]
P. D. Q. Adult Treatment Editorial Board. NonSmall Cell Lung Cancer Treatment (PDQ®): Google Scholar
[16]
Health Professional Version. PDQ Cancer Google Scholar
[17]
Information Summaries. National Cancer Google Scholar
[18]
Institute (US); 2002. Google Scholar
[19]
Alici S, Coskun U, Alkis N et al., Vinorelbine in Google Scholar
[20]
combination with carboplatin followed by singleagent consolidation therapy for unresectable Google Scholar
[21]
localized or metastatic non-small-cell lung Google Scholar
[22]
carcinomas. Asian Pacific journal of cancer Google Scholar
[23]
prevention : APJCP. 2009;10(6):1051-5. Google Scholar
[24]
Bunn PAJr. Worldwide overview of the current Google Scholar
[25]
status of lung cancer diagnosis and treatment. Google Scholar
[26]
Archives of pathology & laboratory medicine. Google Scholar
[27]
Dec 2012;136(12):1478-81. doi:10.5858/ Google Scholar
[28]
arpa.2012-0295-SA Google Scholar
[29]
Di Maio M, Chiodini P, Georgoulias V et al., Google Scholar
[30]
Meta-analysis of single-agent chemotherapy Google Scholar
[31]
compared with combination chemotherapy as Google Scholar
[32]
second-line treatment of advanced non-smallcell lung cancer. Journal of clinical oncology Google Scholar
[33]
: official journal of the American Society of Google Scholar
[34]
Clinical Oncology. Apr 10 2009;27(11):1836-43. Google Scholar
[35]
doi:10.1200/jco.2008.17.5844 Google Scholar
[36]
Fossella FV, Docetaxel in second-line treatment Google Scholar
[37]
of non-small-cell lung cancer. Clinical lung Google Scholar
[38]
cancer. May 2002;3 Suppl 2:S23-8. doi:10.3816/ Google Scholar
[39]
clc.2002.s.010 Google Scholar
[40]
Nguyễn Văn Hiếu. Ung thư học. Nhà xuất bản Y Google Scholar
[41]
học; 2015. Google Scholar
[42]
Shepherd FA, Dancey J, Ramlau R et al., Google Scholar
[43]
Prospective randomized trial of Docetaxel versus Google Scholar
[44]
best supportive care in patients with non-smallcell lung cancer previously treated with platinumbased chemotherapy. Journal of clinical oncology Google Scholar
[45]
: official journal of the American Society of Google Scholar
[46]
Clinical Oncology. May 2000;18(10):2095-103. Google Scholar
[47]
doi:10.1200/jco.2000.18.10.2095 Google Scholar
[48]
Nguyễn Thị Minh Hải, Đánh giá kết quả điều trị Google Scholar
[49]
ung thư phổi không tế bào nhỏ bước hai bằng Google Scholar
[50]
Docetaxel. Luận văn Thạc sỹ y học, Trường đại Google Scholar
[51]
học Y Hà Nội; 2016. Google Scholar
[52]
Nguyễn Thị Hương, Đánh giá kết quả điều trị Google Scholar
[53]
bước 2 ung thư phổi không tế bào nhỏ giai đoạn Google Scholar
[54]
tiến triển bằng Docetaxel tại Bệnh viện K. Luận Google Scholar
[55]
văn bác sỹ chuyên khoa cấp II, Trường đại học Y Google Scholar
[56]
Hà Nội; 2019. Google Scholar
[57]
Trần Khôi, Đánh giá kết quả điều trị docetaxel Google Scholar
[58]
bước 2 trong ung thư phổi không tế bào nhỏ tại Google Scholar
[59]
Bệnh viện Phổi Trung ương. Luận văn thạc sỹ y Google Scholar
[60]
học, Trường đại học Y Hà Nội; 2020. Google Scholar
[61]
Hanna N, Shepherd FA, Fossella FV et al., Google Scholar
[62]
Randomized phase III trial of pemetrexed versus Google Scholar
[63]
Docetaxel in patients with non-small-cell lung Google Scholar
[64]
cancer previously treated with chemotherapy. Google Scholar
[65]
Journal of clinical oncology : official journal Google Scholar
[66]
of the American Society of Clinical Oncology. Google Scholar
[67]
May 1 2004;22(9):1589-97. doi:10.1200/ Google Scholar
[68]
jco.2004.08.163 Google Scholar
[69]
Fossella FV, DeVore R, Kerr RN et al., Google Scholar
[70]
Randomized phase III trial of Docetaxel versus Google Scholar
[71]
vinorelbine or ifosfamide in patients with Google Scholar
[72]
advanced non-small-cell lung cancer previously Google Scholar
[73]
treated with platinum-containing chemotherapy Google Scholar
[74]
regimens. The TAX 320 Non-Small Cell Lung Google Scholar
[75]
Cancer Study Group. Journal of clinical oncology Google Scholar
[76]
: official journal of the American Society of Google Scholar
[77]
Clinical Oncology. Jun 2000;18(12):2354-62. Google Scholar
[78]
doi:10.1200/jco.2000.18.12.2354 Google Scholar